Anti-cancer activity of dose-fractioned mPE +/− bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients

BACKGROUND: Results from the BEVA2007 trial, suggest that the metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), shows anti-angiogenic and immunological effects and is a safe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Thorac Dis
Hauptverfasser: Pastina, Pierpaolo, Nardone, Valerio, Croci, Stefania, Battaglia, Giuseppe, Vanni, Francesca, Bellan, Cristiana, Barbarino, Marcella, Ricci, Veronica, Costantini, Susan, Capone, Francesca, Botta, Cirino, Zarone, Mayra Rachele, Misso, Gabriella, Boccellino, Mariarosaria, Caraglia, Michele, Giordano, Antonio, Paladini, Piero, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Cusi, Maria Grazia, Pirtoli, Luigi, Correale, Pierpaolo
Format: Artigo
Sprache:Inglês
Veröffentlicht: AME Publishing Company 2017
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5708460/
https://ncbi.nlm.nih.gov/pubmed/29221287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2017.08.68
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge